{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:20:25Z","timestamp":1788258025118,"version":"build-2803163510"},"reference-count":26,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dent. J.","Dentistry Journal"],"abstract":"<jats:p>Background\/Objectives: Chimeric antigen receptor T-cell (CAR-T) therapy has been approved for the management of relapsed and refractory hematologic malignancies, transforming the oncologic landscape and producing durable remissions in patient populations with limited alternatives. The systemic adverse events of CAR-T are well characterized; however, the orofacial adverse events have not been well described. The objective of this study is to leverage a large, de-identified, real-world dataset to (1) estimate the prevalence of orofacial adverse events following CAR-T, (2) compare event rates with the general population, and (3) directly contrast the orofacial toxicity burden of CAR-T with that observed after hemopoietic stem cell transplant (HSCT). Methods: We performed a retrospective cohort study using de-identified electronic health record data from TriNetX. CAR-T and HSCT cohorts were identified via RxNorm and procedure codes; a non-exposed control cohort was included. Patients with prior orofacial conditions or confounding therapies were excluded. New adverse orofacial events within one year were identified by International Classification of Diseases, 10th Revision (ICD-10) codes. Cohorts were 1:1 propensity-matched by age and sex; associations were estimated as odds ratios with two-sided 95% CIs. Results: In 1142 CAR-T recipients (mean age of 62), gastroesophageal reflux disease (GERD) was most frequent (5.18%). Oral mucosal events included stomatitis in 1.52%, mucositis in 1.31%, and lichenoid reactions in 1.03%. Dysphagia occurred in 1.8% and oral candidiasis in 1.6%. Several severe oral conditions were absent. Compared with the general population (CART vs. general population): mucositis\u2014[12\/995 vs. 0\/1112] (OR 28.3)\u2014and stomatitis\u2014[16\/987 vs. 0\/1119] (OR 38)\u2014risks were significantly increased, while CAR-T patients had significant lower risks of mucosal complications than HSCT recipients in this analysis (CART vs. HSCT): mucositis\u2014[1.21% vs. 3.72%] (OR 0.316) and stomatitis\u2014[1.42% vs. 3.91%] (OR 0.354). Conclusions: CAR-T therapy carries a distinct and generally lower orofacial toxicity burden than HSCT, but targeted dental assessment and prospective surveillance remain important to optimize supportive care for cellular therapy recipients.<\/jats:p>","DOI":"10.3390\/dj14090549","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:48:36Z","timestamp":1788256116000},"page":"549","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric Antigen Receptor T-Cell Therapy Is Associated with Low Absolute Rates of Orofacial Adverse Events and Significantly Less When Compared to Hemopoietic Stem Cell Therapy"],"prefix":"10.3390","volume":"14","author":[{"given":"Stella O.","family":"Oyewole","sequence":"first","affiliation":[{"name":"College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Butler","sequence":"additional","affiliation":[{"name":"Oral Medicine, Dental Oncology and Urgent Care Unit, Missouri School of Dentistry and Oral Health, A.T. Still University, 1500 Park Avenue, St. Louis, MO 63104, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"given":"Sagun D.","family":"Goyal","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant & Cellular Therapy Unit, Department of Medicine, School of Medicine, Saint Louis University, St. Louis, MO 63104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4602-9469","authenticated-orcid":false,"given":"Adepitan A.","family":"Owosho","sequence":"additional","affiliation":[{"name":"Oral Medicine, Dental Oncology and Urgent Care Unit, Missouri School of Dentistry and Oral Health, A.T. Still University, 1500 Park Avenue, St. Louis, MO 63104, USA"},{"name":"Robert Ebert and Greg Stubblefield Head and Neck Tumor Center, Siteman Cancer Center, St. Louis, MO 63108, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","article-title":"Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: A single-arm, phase 1\u20132 trial","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12929-023-00982-8","article-title":"Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies","volume":"30","author":"Yang","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_14","first-page":"621","article-title":"Oral manifestations and dental management in patients undergoing CAR-T cell therapy: A retrospective observational study","volume":"34","author":"Menti","year":"2026","journal-title":"Support. Care Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lei, W., Xie, M., Jiang, Q., Xu, N., Li, P., Liang, A., Young, K.H., and Qian, W. (2021). Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis. Cancers, 13.","DOI":"10.3390\/cancers13153912"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"103267","DOI":"10.1016\/j.eclinm.2025.103267","article-title":"Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: A systematic review and meta-analysis","volume":"84","author":"Zhu","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Guo, Z., Ding, Y., Wang, M., Zhai, Q., Liu, J., and Du, Q. (2024). Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study. Pharmaceuticals, 17.","DOI":"10.3390\/ph17081025"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"378281","DOI":"10.1155\/2014\/378281","article-title":"Oral complications in hematopoietic stem cell recipients: The role of inflammation","volume":"2014","author":"Haverman","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Eichhorn, S., Rudin, L., Ramasamy, C., Varsani, R., Padhi, P., Nassour, N., Meleveedu, K., Epstein, J.B., Semegran, B., and Pili, R. (2025). Elevated Likelihood of Infectious Complications Related to Oral Mucositis After Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis of Outcomes and Risk Factors. Cancers, 17.","DOI":"10.3390\/cancers17162657"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/bmt.2011.63","article-title":"Long-term oral complications of allogeneic haematopoietic SCT","volume":"47","author":"Hull","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"lgz007","DOI":"10.1093\/jncimonographs\/lgz007","article-title":"Oral Complications of Chronic Graft-Versus-Host Disease","volume":"2019","author":"Pavletic","year":"2019","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"ref_22","first-page":"15","article-title":"Oral toxicities following CAR T-cell therapy: An overlooked clinical reality","volume":"9","author":"Somay","year":"2025","journal-title":"Acta Sci. Dent. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e19505","DOI":"10.1200\/JCO.2024.42.16_suppl.e19505","article-title":"Risk of gastrointestinal adverse events associated with chimeric antigen receptor T-cell therapy (CAR-T): A nationwide analysis","volume":"42","author":"Khan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/COC.0000000000000596","article-title":"Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy","volume":"42","author":"Tang","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_25","first-page":"716","article-title":"Neutropenic ulcers in oncology: Terminology, diagnosis, and management","volume":"31","author":"Guneri","year":"2023","journal-title":"Support. Care Cancer"},{"key":"ref_26","first-page":"853","article-title":"MASCC\/ISOO Clinical Practice Statement: Dental evaluation and management prior to treatment for hematologic malignancies and CAR T-cell therapy","volume":"33","author":"Zadik","year":"2025","journal-title":"Support. Care Cancer"}],"container-title":["Dentistry Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2304-6767\/14\/9\/549\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:08:32Z","timestamp":1788257312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2304-6767\/14\/9\/549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["dj14090549"],"URL":"https:\/\/doi.org\/10.3390\/dj14090549","relation":{},"ISSN":["2304-6767"],"issn-type":[{"value":"2304-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}